Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13665657 | 0.88 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2HPGDHTTMEN1 | |
| SCHEMBL12635428 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL11939338 | 0.85 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL289802 | 0.81 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL13076776 | 0.80 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2HPGDHTTMAPT | |
| SCHEMBL17863709 | 0.78 | KMT2A (0.44) | ALDH1A1HPGDLMNANPSR1MEN1 | |
| SCHEMBL13075779 | 0.77 | KMT2A (0.46) | ALDH1A1HPGDHTTLMNAMEN1 | |
| SCHEMBL11939025 | 0.74 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL12635413 | 0.74 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2HPGDHTTKMT2A | |
| SCHEMBL1038307 | 0.73 | HPGD (0.45) | ALDH1A1SMN1; SMN2HPGDHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427469-B1 | PROCESS FOR THE PREPARATION OF RUTHENIUM METATHESIS COMPLEX CATALYSTS | HOFFMANN LA ROCHE (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8288534-B2 | Process for the preparation a ruthenium complex | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288534-B2 | Process for the preparation a ruthenium complex | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288534-B2 | Process for the preparation a ruthenium complex | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2276725-B1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | HOFFMANN LA ROCHE (CH) | 2012-07-04 | — | — | EP | disclosed |
| EP-2276725-B1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | HOFFMANN LA ROCHE (CH) | 2012-07-04 | — | — | EP | disclosed |
| EP-2427469-A1 | PROCESS FOR THE PREPARATION OF RUTHENIUM METATHESIS COMPLEX CATALYSTS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939668-B2 | Ruthenium complexes as catalysts for metathesis reactions | ROCHE PALO ALTO LLC (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2276725-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. Hoffmann-La Roche AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| WO-2010127964-A1 | PROCESS FOR THE PREPARATION OF RUTHENIUM METATHESIS COMPLEX CATALYSTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010127964-A1 | PROCESS FOR THE PREPARATION OF RUTHENIUM METATHESIS COMPLEX CATALYSTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | ROCHE PALO ALTO LLC | 2009-11-05 | — | — | US | disclosed |
| WO-2009124853-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009124853-A1 | NEW RUTHENIUM COMPLEXES AS CATALYSTS FOR METATHESIS REACTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286403-A1 | PROCESS FOR THE PREPARATION A RUTHENIUM COMPLEX | CYP3A4, CYP3A5, CYP3A7 | ALDH1A1 1321/4885SMN1; SMN2 4452/4885HPGD 621/4885 |
| US-20090275714-A1 | New Ruthenium Complexes as Catalysts for Metathesis Reactions | HABP2, CYP3A7, ACE | ALDH1A1 1641/4885SMN1; SMN2 4639/4885HPGD 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.